<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The objective of this study was to investigate the effect of small molecule inhibitors of <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase-3β (GSK-3β) on <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell growth and survival </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Analysis of cytotoxicity and cell proliferation was conducted using the MTS assay, cell-cycle analysis, and division tracking </plain></SENT>
<SENT sid="2" pm="."><plain><z:mpath ids='MPATH_3'>Apoptosis</z:mpath> was investigated by Annexin-V/<z:chebi fb="0" ids="52304">7-aminoactinomycin D</z:chebi> and caspase-3 expression </plain></SENT>
<SENT sid="3" pm="."><plain>The effect of GSK-3β inhibitors was also tested in vivo in an animal model of <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Gene expression analysis was performed to identify the genes modulated by GSK-3β inhibition in <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: GSK-3β inhibitors suppress cell growth and induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in seven <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines of diverse origin, four <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>, one <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and one <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> samples </plain></SENT>
<SENT sid="6" pm="."><plain>GSK-3β inhibitors are cytotoxic for rapidly dividing clonogenic <z:hpo ids='HP_0001909'>leukemia</z:hpo> blasts, and higher doses of the inhibitors are needed to eliminate primitive <z:hpo ids='HP_0001909'>leukemia</z:hpo> progenitor/stem cells </plain></SENT>
<SENT sid="7" pm="."><plain>Slow cell-division rate, low drug uptake, and interaction with bone marrow stroma make <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells more resistant to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by GSK-3β inhibitors </plain></SENT>
<SENT sid="8" pm="."><plain>Global gene expression analysis combined with functional approaches identified multiple genes and specific signaling pathways modulated by GSK-3β inhibition </plain></SENT>
<SENT sid="9" pm="."><plain>An important role for Bcl2 in the regulation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induced by GSK-3β inhibitors was defined by expression analysis and confirmed by using pharmacological inhibitors of the protein </plain></SENT>
<SENT sid="10" pm="."><plain>In vivo administration of GSK-3β inhibitors delayed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation in a mouse <z:hpo ids='HP_0001909'>leukemia</z:hpo> model </plain></SENT>
<SENT sid="11" pm="."><plain>GSK-3β inhibitors did not affect hematopoietic recovery following irradiation </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Our data support further evaluation of GSK-3β inhibitors as promising novel agents for therapeutic intervention in <z:hpo ids='HP_0001909'>leukemia</z:hpo> and warrant clinical investigation in <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients </plain></SENT>
</text></document>